{"analyses":[{"ciPctValue":"95","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0005","statisticalMethod":"Chi-squared","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.6","upperLimit":"7.2","value":"4.4"},{"groupId":"OG001","lowerLimit":"9.6","upperLimit":"19.3","value":"14.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"204"},{"groupId":"OG001","value":"201"}],"units":"Participants"}],"description":"Tumor Overall Response Rate (ORR) (only in patients with measurable disease):\n\nObjective responses (Complete Response and Partial Response) for measurable disease as assessed by investigators according to RECIST criteria.\n\nComplete Response (CR) is defined as: Disappearance of all target lesions. Partial Response (PR) is defined as: At least a 30% decrease in the sum of longest diameter (LD) of target lesions taking as reference baseline sum LD.\n\nConfirmation of objective responses will be performed by repeat tumor imaging (CT scans, MRI, bone scans) after the first documentation of response.","dispersionType":"95% Confidence Interval","groups":[{"description":"mitoxantrone 12 mg/m\\^2 (Day 1) by intravenous (IV) every 3 weeks, and prednisone 10 mg orally given daily","id":"OG000","title":"Mitoxantrone + Prednisone"},{"description":"cabazitaxel 25 mg/m\\^2 (Day 1) by intravenous (IV) every 3 weeks, and prednisone 10 mg orally given daily","id":"OG001","title":"Cabazitaxel + Prednisone"}],"paramType":"NUMBER","populationDescription":"Tumor response rate was evaluated only for patients, in the Intention-To-Treat (ITT) population, with measurable disease by Response Evaluation Criteria in Solid Tumor (RECIST).","reportingStatus":"POSTED","timeFrame":"From the date of randomization up to 104 weeks (study cut-off)","title":"Overall Tumor Response","type":"SECONDARY","unitOfMeasure":"percentage of participants"}